Early and Late Prognosis in Patients With Guillain-Barre Syndrome

Wenzhou Medical University

Status and phase: Enrolling; Phase 4

Conditions: Guillain-Barre Syndrome

Treatments: Drug: Methylprednisolone 500 MG Injection; Drug: Intravenous Immunoglobulins, Human

Study type: Interventional

Funder types: Other

Identifiers

NCT06041451

Dengbinbin

Details and patient eligibility

About

The goal of this observational study is to explore significant indicators to predict the early prognosis and late prognosis in patients with Guillain-Barre syndrome.

Full description

This is a multicenter study(approximately three) with over 450 subjects.Clinical data were collected by consulting the patient's electronic history. The data included demographic information, blood biochemical markers, clinical characteristics and electromyography. All participants provided their written informed consent to participate in this study.

Enrollment: 450 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients fulfilled clinical, biological, and electrophysiology criteria for Guillain-barre syndrome.

Exclusion criteria

• nonidiopathic Guillain-barre syndrome and Miller Fisher syndrome

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

450 participants in 4 patient groups

immunoglobulin group

Experimental group

Description:

This group of patients was treated with intravenous immunoglobulin(30g ivgtt qd) for 5 days

Treatment:

Drug: Intravenous Immunoglobulins, Human

methylprednisolone group

Experimental group

Description:

This group of patients was treated with methylprednisolone 500 MG Injection

Treatment:

Drug: Methylprednisolone 500 MG Injection

control group

No Intervention group

Description:

This group of patients was treated without immunoglobulin or hormone

mixed group

Experimental group

Description:

This group of patients was treated both with intravenous immunoglobulin and methylprednisolone.

Treatment:

Drug: Intravenous Immunoglobulins, Human

Drug: Methylprednisolone 500 MG Injection